Harpoon Therapeutics Inc
F:5HT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
National Bank of Greece SA
OTC:NBGIF
|
GR |
|
S
|
Shanghai Bio-heart Biological Technology Co Ltd
HKEX:2185
|
CN |
Harpoon Therapeutics Inc
Total Current Assets
Harpoon Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Harpoon Therapeutics Inc
F:5HT
|
Total Current Assets
$54.7m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Harpoon Therapeutics Inc
Glance View
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. The company is headquartered in South San Francisco, California and currently employs 99 full-time employees. The company went IPO on 2019-02-08. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.
See Also
What is Harpoon Therapeutics Inc's Total Current Assets?
Total Current Assets
54.7m
USD
Based on the financial report for Dec 31, 2022, Harpoon Therapeutics Inc's Total Current Assets amounts to 54.7m USD.
What is Harpoon Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
13%
Over the last year, the Total Current Assets growth was -60%. The average annual Total Current Assets growth rates for Harpoon Therapeutics Inc have been -29% over the past three years , 13% over the past five years .
